Company news

VolitionRX Limited news in 2026

VolitionRX Limited's news releases, calls and decks from 2026, newest first.

View company

VolitionRx Signs LOI with Missionpharma to explore the Development and Launch of Volition's Lateral Flow Technology for NETosis Worldwide

October 27, 2026

VolitionRx Limited Announces $500,000 Partial Pre-Payment of Convertible Note in Cash

October 27, 2026

VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027

September 14, 2026

Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis

August 26, 2026

VolitionRx Announces Second Quarter 2026 Financial Results and Business Update

August 13, 2026

Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients

August 12, 2026

VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update

August 12, 2026

Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology

August 5, 2026

Volition Advances Nu.Q® NETs Platform Towards Commercialization

July 30, 2026

VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test

July 7, 2026

VolitionRx Announces Collaboration with Sysmex

June 17, 2026

VolitionRx Announces Pricing of $4.6 Million Public Offering

June 7, 2026

VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring

June 3, 2026

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets

May 27, 2026

VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update

May 14, 2026

VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

May 11, 2026

VolitionRx Announces Submission of Manuscript for Nu.Q® Vet Cancer Test in Cats

May 6, 2026

Volition Announces Breakthrough Finger-Prick Detection of Nucleosomes; Expanding Global Market Potential for Sepsis Testing

April 29, 2026

VolitionRx Announces Acceptance of Compliance Plan by NYSE American

April 23, 2026

Volition Launches rNuQ™ Webshop Broadening Product Range

April 20, 2026

VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium

March 31, 2026

Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients

March 30, 2026

Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference

March 26, 2026

VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update

March 25, 2026

Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA

March 18, 2026

Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems

March 6, 2026

VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution

February 25, 2026

Volition Announces the Appointment of New Distributor for Nu.Q® Discover

February 10, 2026

VolitionRx Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

February 9, 2026

Volition Sponsors Symposium at 15th Conference of the European Hidradenitis Suppurativa Foundation

February 4, 2026

VolitionRx Limited Announces the Preparation of Reimbursement Submission for its Nu.Q® Cancer Assays

January 30, 2026

Volition Announces Data to Support Use of Nu.Q® NETs in New Indication

January 27, 2026

Volition Continues to Extend Access to Nu.Q® Vet Cancer Test

January 20, 2026

Volition Sponsors Symposium at Veterinary Meeting and Expo

January 16, 2026

VolitionRx Secures $2.0 Million in Funding

January 8, 2026

VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats

January 8, 2026

Calls in 2026

Decks in 2026